The outlook revision is based on a number of financial and strategic challenges, including an operating loss related to Geisinger’s health plan’s exchange product.
Moody’s Investors Service also affirmed the “Aa2” and “Aa2/VMIG 1” ratings on Geisinger’s outstanding bonds. The rating affirmations are based on Geisinger’s large size, leading market position and exceptional clinical reputation.
More articles on healthcare finance:
Surprise billing legislation stalls again on East Coast
For-profit hospital stock report: Week of Nov. 21-25
Medicare cancer patients without additional coverage hit with high out-of-pocket costs: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.